Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine and Cisplatin in Platinum-Resistant Ovarian Cancer
NCT00081276Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triapine in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 5 years and Adverse Events up to 5 years. Started Jul 2005; status: completed.
02
Drugs
triapine
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00081276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081276.